Publications
529
Citations
9,616
Est. group size
~1
Recurring co-author estimate
Active years
41
Publishing since 1986
Typically publishes in teams of ~12 · 7% small-team papers (≤3 authors) · across 87 venues
- P0735 Safety and Efficacy of Ustekinumab in Indian Patients with Moderate to Severe Crohn’s Disease: A Multicentre, Interventional, Phase IV study
Journal of Crohn s and Colitis · 2026
- Itacitinib plus calcineurin inhibitor–based therapy for prophylaxis of graft-versus-host disease: GRAVITAS-119 results
Research Square · 2026
- A Randomized Phase <scp>II</scp> Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma
American Journal of Hematology · 2026
- Pan-UK Biobank genome-wide association analyses enhance discovery and resolution of ancestry-enriched effects
Nature Genetics · 2025
- Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma
Journal of Clinical Oncology · 2025
- A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies
Clinical Lymphoma Myeloma & Leukemia · 2025
- Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy Studies
Transplantation and Cellular Therapy · 2025
- POSTER: IBCL-675 Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Shows High Clinical Activity and Tolerable Safety in an Ongoing Phase 1a/b Study in Patients With Waldenström Macroglobulinemia (WM)
Clinical Lymphoma Myeloma & Leukemia · 2025
- Ceramic-on-ceramic bearings: can we avoid the complications? Long-term outcomes of big head CoC bearings in primary total hip arthroplasty
European Journal of Orthopaedic Surgery & Traumatology · 2025
- 403P: Higher predilection of driver mutation positive squamous lung cancer in the Asia Pacific region
Journal of Thoracic Oncology · 2025
- IBCL-675: Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Shows High Clinical Activity and Tolerable Safety in an Ongoing Phase 1a/b Study in Patients With Waldenström Macroglobulinemia (WM)
Clinical Lymphoma Myeloma & Leukemia · 2025
- Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial
Blood · 2025
- CLL-563: Bexobrutideg (NX-5948), a Novel Bruton's Tyrosine Kinase Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Findings from an Ongoing Phase 1a Study
Clinical Lymphoma Myeloma & Leukemia · 2025
- Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study.
Blood · 2025
- Docirbrutinib (AS-1763), a novel non-COVALENT pan-mutant BTK inhibitor, demonstrates durable clinical responses in patients with previously treated B-cell malignancies: Data from an ongoing Phase 1b study
Blood · 2025
- Blood×126
- Clinical Lymphoma Myeloma & Leukemia×44
- Transplantation and Cellular Therapy×31
- Biology of Blood and Marrow Transplantation×31
- Journal of Clinical Oncology×22
- Daniel Li
Medicine · The Ohio State University
- Audrey M. Sigmund
Medicine · The Ohio State University
- Jang Hwan Cho
Medicine · University of Michigan
- Utkarsh Acharya
Medicine · The Ohio State University
- Monalisa Ghosh
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile